Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 12/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAP3K13 | O43283 | 3/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20742465 | 0.79 | MAP3K12 (0.45) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL20742448 | 0.75 | MTOR (0.35) | MAP3K12MTORPIK3CAATR | |
| SCHEMBL20742614 | 0.75 | ATR (0.46) | MTORPIK3CAATR | |
| SCHEMBL20742611 | 0.75 | ATR (0.46) | MTORPIK3CAATR | |
| SCHEMBL20745332 | 0.74 | HCRTR2 (0.37) | — | |
| SCHEMBL20742754 | 0.72 | KCNQ3 (0.49) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL26141926 | 0.72 | MAP3K12 (0.45) | KCNQ3KCNQ2MAP3K12MTORPIK3CA | |
| SCHEMBL20745766 | 0.72 | CA12 (0.47) | MTORPIK3CA | |
| SCHEMBL31434277 | 0.71 | NR1H2 (0.35) | — | |
| SCHEMBL22320385 | 0.71 | ACACB (0.38) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KCNQ3 3568/4885KCNQ2 3731/4885MAP3K12 2829/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | KCNQ3 3568/4885KCNQ2 3731/4885MAP3K12 2829/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KCNQ3 3568/4885KCNQ2 3731/4885MAP3K12 2829/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KCNQ3 3568/4885KCNQ2 3731/4885MAP3K12 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.